Observations placeholder




Type of Spiritual Experience


Number of hallucinations: 261


A description of the experience


marketed as Revlimid  is a derivative of thalidomide introduced in 2004.  It was initially intended as a treatment for multiple myeloma but is also used for a group of hematological disorders known as myelodysplastic syndromes (MDS). In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of the microenvironment support for tumor cells, and immunomodulatory role. In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, and by immunomodulatory activity.

Lenalidomide, like its parent compound thalidomide, may cause venous thromboembolism (VTE), a potentially serious complication with their use. Other potential side effects are thrombosis, pulmonary embolus, and hepatotoxicity, as well as bone marrow toxicity resulting in neutropenia and thrombocytopenia.  The drug is being investigated for possibly increasing the risk of developing Stevens-Johnson syndrome, a life-threatening condition affecting the skin.

On Dec, 29, 2016 117,888 people reported to have side effects when taking Revlimid.  Among them, 261 people (0.22%) have Hallucination

Time on Revlimid when people have Hallucination  :

  < 1 month 1 - 6 months 6 - 12 months 1 - 2 years 2 - 5 years 5 - 10 years 10+ years
Hallucination 60.00% 32.73% 3.64% 1.82% 1.82% 0.00% 0.00%

Gender of people who have Hallucination when taking Revlimid  :

  Female Male
Hallucination 40.96% 59.04%

Age of people who have Hallucination when taking Revlimid  :

  0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Hallucination 0.00% 0.00% 0.00% 0.00% 0.00% 1.29% 9.68% 89.03%


On Jan, 22, 2017   117,888 people reported to have side effects when taking Revlimid.
Among them, 12,529 people (10.63%) have Death

The source of the experience


Concepts, symbols and science items



Science Items


Activities and commonsteps